

Adverse drug reactions associated with asthma medications in children: systematic review of clinical trials

Lise Aagaard · Ebba Holme Hansen

Received: 29 October 2013 / Accepted: 11 February 2014 / Published online: 23 February 2014
© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Abstract *Background* Respiratory medications are frequently prescribed for use in children. Several studies have reported information on the safety of asthma medications in clinical studies in adults, but information about safety in children is scarce. *Objective* To review published clinical trials on the occurrence and characteristics of adverse drug reactions (ADRs) in children, reported for asthma medications licensed for paediatric use. *Methods* We systematically reviewed the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines. PubMed, Embase, Cochrane Library, PsycINFO, IPA, and CINAHLs databases were searched from origin until July 2013 for studies reporting ADRs for beta2-receptor agonists, inhaled corticosteroids, leukotriene receptor antagonists and combination products in children from birth to age 17. Information on ADR reporting rates, age and gender, type and seriousness of ADRs, design, setting, observation period, type of assessors, and funding sources was extracted from the articles.

Results Literature searches resulted in 162 potential relevant articles. However only 12 of these studies were included in this review as they reported information about ADR rates from use of salmeterol, formoterol, fluticasone, montelukast, zafirlukast and budesonide/formoterol in children. The total population was approximately 3,000 children; the majority was 6- to 11-year-olds and two thirds of these were boys. The observation period varied from 1 to 22 months. The most frequently reported ADRs were exacerbation of asthma, respiratory tract infection, cough, fever and headache. Only few ADRs were rated as being serious, however a number of children dropped out of the clinical trials due to serious ADRs, and, therefore, the real number of serious ADRs is probably higher. *Conclusions* Few clinical trials reporting ADRs from use of asthma medications in children were identified in the literature. These studies reported only a few types of ADRs, the majority being non-serious.

Keywords Adverse drug reactions · Asthma · Children · Pharmacovigilance · Pediatric indication

Electronic supplementary material The online version of this article (doi:10.1007/s11096-014-9924-y) contains supplementary material, which is available to authorized users.

L. Aagaard (✉)
Faculty of Health Sciences, Institute of Public Health, University of Southern Denmark, J.B. Winsløvs Vej 19, 5000 Odense C, Denmark
e-mail: laagaard@health.sdu.dk

E. H. Hansen
Section for Social and Clinical Pharmacy, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark

Impacts on Practice

- A large number of clinical trials with respiratory medicines conducted in children can be found in the literature, but only few report information about adverse drug reactions (ADRs).
- Studies of spontaneous ADR reports on respiratory medications submitted to national pharmacovigilance databases must be conducted in order to increase knowledge about ADRs occurring in children.
- There is a need for more population-based studies to collect information about possible ADRs in order to

estimate the prevalence of rarely occurring and unexpected ADRs.

Introduction

Respiratory medications (ATC group R) are prescribed frequently for use in children [1]. In a cohort of approximately 48,000 Danish children one in three children below 3 years of age received prescriptions for anti-asthmatics, mainly oral beta-2 agonists [1]. In the 7 to 15-year-old group 6 % of the children were prescribed anti-asthmatics [1]. Studies from other western countries have reported similar results showing that the level of exposure to respiratory medications was highest in early childhood [2]. In a cohort of 374,068 patients in the US aged 6–11-year the majority (42 %) started their treatment with a prescription of a short-acting beta2-agonists. Other common starting medications was inhaled corticosteroids (ICS) (16 %) [3]. Despite the widespread use of these medications, information about safety in children is scarce [2]. Analysis of spontaneous reports submitted to regulatory authorities in Denmark from 1998 to 2007 showed that ADRs reported for respiratory medications constituted 2 % of all ADRs reported in children from birth to age 17 [4]. Analyses of ADR reports submitted to the WHO database Vigibase from 1995 to 2005 showed that 11 % of all ADR reports in children were for respiratory medications compared to 7 % in adults [5]. The Vigibase study did not provide information about type of reported ADRs and suspected medications [5], so the impact of the ADRs is unknown. A study analyzing ADRs reported to the Dutch national ADR database for ICS from 1984 to 2004 in children below 18 years found that the majority of reported ADRs associated with use of ICS were psychiatric symptoms, growth retardation, rash, alopecia and headache [6]. In 2008 the FDA issued safety alerts requiring manufacturers of leukotriene-receptor antagonists to include suicide and neuropsychiatric events as a precaution in the product information for adults. It remains unclear whether these ADRs may occur in children [6]. Clinical guidelines recommend ICS and beta2-receptor agonists as first-line standard treatment in children [2]. As no articles have previously reviewed the ADR patterns following use of these medications in children, we wanted to review ADRs reported in paediatric clinical trials for these therapeutic groups compared to other paediatric medications licensed for treatment of asthma.

Aim of the study

To review published clinical trials on the occurrence and characteristics of ADRs in children, reported for asthma medications licensed for paediatric use.

Methods

Literature searches

Literature searches were performed in PubMed, Embase, Cochrane Library, IPA, PsycInfo and CINAHL (whole databases from origin without language restriction). Table 1 lists the asthma medications licensed for paediatric use and their approved paediatric indication with respect to age and anatomical classification [ATC] group R. The selected medications were licensed for treatment of asthma according to international treatment guidelines and they had a paediatric indication listed in the official product information issued by the Danish Health and Medicines Authority and/or the European Medicines Agency. Therefore we searched with the terms “adrenergic beta-2-receptor agonists” [MESH], “ICS”, “leukotriene receptor antagonists” [MESH], “cholinergic antagonists” [MESH],” and “anti-immunoglobulin-E-antibodies” combined with any of the following: “adverse drug reaction,” “side effect” and “adverse event”. Further searches were conducted in PubMed using the key words “adverse drug reaction” plus each of the following: “salbutamol”, “levosalbutamol”, “terbutaline”, “pirbuterol”, “fenoterol”, “salmeterol”, “formoterol”, “bambuterol”, “budenosid”, “fluticasone”, “mometason”, “beclometason”, “montelukast” and “zafirlukast”, and “ipratropium”. Additionally, the following search terms: “cortisol suppression”, “exacerbation rate”, “growth retardation rate” and “psychiatric” combined with “asthma medications” were also included in the searches, as such events have often been reported in clinical trials for asthma medicines. Table 2 provides further details of the search strategy, which was constructed based on advice from an information specialist. Reference lists of identified articles were also screened for additional potentially relevant articles. The clinical trials databases www.clinicaltrials.gov and www.ctr.gsk.co.uk were searched for additional studies. Literature searches were updated until June 2013.

Study selection

Both authors independently screened the retrieved abstracts to identify studies relevant for the review. Potentially relevant articles were retrieved in full text and further screened for inclusion. To be considered relevant for this review, articles had to be peer-reviewed and report ADRs associated with the use of asthma medications licensed for paediatric use displayed as ADR rates (%) in children from birth to age 17. We also included studies not reporting ADRs as rates if the provided data allows for ADR rate calculation. Studies located in the US clinical trials database were excluded, as they provided insufficient information about reported ADRs.

Table 1 Medicines with paediatric indication used to treat asthma according to paediatric guidelines

Therapeutic group (s)	ATC group	Medicine (s)	Paediatric indication (age) ^a (months)
Short-acting beta2-agonists	R03AC02	Salbutamol (Ventoline [®])	≥18
	R03AC03	Terbutaline (Bricanyl [®])	≥3
	R03AC04	Fenoterol (Berotec [®])	≥0
Long-acting beta2-agonists (LABAs)	R03AC12	Salmeterol (Serevent [®])	≥4
	R03AC13	Formoterol (Foradil [®])	≥5
	R03CC12	Bambuterol (Bambec [®])	≥2
Corticosteroids	R03BA02	Budesonid (Spirocort [®])	≥0
	R03BA05	Fluticasone (Flixotide [®])	≥1
	R01AD09	Mometason (Asmanex [®])	≥12
	R03BA01	Beclometason (Beclomet [®])	≥5
Leukotriene receptor antagonists	R03DC03	Montelukast (Singulair [®])	≥15
	R03DC01	Zafirlukast (Accolate [®])	≥5
Combination products	R03AK03	Ipratropium/Fenoterol (Berodual [®])	≥6
	R03AK06	Salmeterol/Fluticasone (Seretide [®])	≥4
	R03AK07	Budesonid/Formoterol (Symbicort [®])	≥12

^a Product Information available at the website: www.produktinformation.dk

Data extraction

Data from included articles were extracted using a standard form, one for each article. The following information was recorded: authors, publication year, country, study design, dosage, comparator, observation period (weeks), size of study populations, age and gender of included population, ADR reporting rates in percentage and information about funding. ADR reporting rates were listed as reported in the original articles. In placebo-controlled studies, information was extracted about ADR reporting rates for the placebo populations as well as dropout figures. We also recorded information about who had assessed the ADRs and if reported ADRs were classified as being serious. The first author extracted data, while the second author checked and verified all cases. Reporting was conducted in the form recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and checklist [7] (see appendix 1).

Definition and seriousness of reported ADR

It was not feasible to apply a common definition of ADRs across studies, as only few of the included papers have specified the applied ADR definitions and causality assessment criteria. In Pearlman et al. 2000 [12] reported adverse event data were tabulated using COSTART (coding symbols for thesaurus of ADRs) terminology. Tal et al. [19] stated that reported adverse events were evaluated with respect to intensity and causality. Hoekx et al. [10] defined a serious ADR as one resulting in death, life-threatening, requiring hospitalization or prolongation of

Table 2 Search strategy: complete databases were searched until June 2013

Search term (mesh/free text)
Adrenergic beta-2-receptor agonists AND adverse drug reaction
Adrenergic beta-2-receptor agonists AND side effect
Adrenergic beta-2-receptor agonists AND adverse event
Inhaled corticosteroids AND adverse drug reaction
Inhaled corticosteroids AND side effect
Inhaled corticosteroids AND adverse event
Leukotriene receptor antagonists AND adverse drug reaction
Leukotriene receptor antagonists AND side effect
Leukotriene receptor antagonists AND adverse event
Adverse drug reaction AND salbutamol
Adverse drug reaction AND levosalbutamol
Adverse drug reaction AND terbutaline
Adverse drug reaction AND pirbuterol
Adverse drug reaction AND fenoterol
Adverse drug reaction AND salmeterol
Adverse drug reaction AND formoterol
Adverse drug reaction AND bambuterol
Adverse drug reaction AND budesonid
Adverse drug reaction AND fluticasone
Adverse drug reaction AND mometasone
Adverse drug reaction AND beclometason
Adverse drug reaction AND montelukast
Adverse drug reaction AND zafirlukast
Cortisol suppression AND asthma medication
Exacerbation rate AND asthma medication
Growth rate retardation AND asthma medication
Psychiatric AND asthma medication

existing hospitalization, resulting in persistent or significant disability/incapacity in the reporter's opinion, a congenital anomaly/birth defect and other medically important conditions. Other reactions were classified as non-serious.

Results

In total, 162 potentially relevant references reporting ADRs from use of the asthma medications listed in Table 1 were identified during the database searches and reference screenings. Figure 1 provides an overview of the review process and reasons for exclusion. Thirteen studies were excluded after the abstracts, and 149 studies were retrieved for full text review. Of these studies, sixteen were later excluded as they reported mixed data on children and adults did not allow for identification of children. Seven meta-analyses and 2 reviews were excluded as they reported information from original studies already included. Also excluded were two studies reporting data from

subgroup analyses of already included studies, and 43 studies in which ADRs were reported only as number of children with an ADR. Eventually, 12 articles corresponding to 13 intervention studies were included. Table 3 presents the study characteristics of the included studies. The included studies were multicenter studies conducted in several countries and the pharmaceutical companies producing the respective medications sponsored all studies. Two studies were found for long-acting beta2-agonists [8, 9], one study for corticosteroids [10], eight studies for leukotriene receptor antagonists [11–18] and one study for the combination product budesonide/formoterol [19]. No studies were located that reported ADR occurrence in children for short-acting beta2-agonists, bambuterol (long-acting beta2-agonist) or the combination products ipratropium/fenoterol and salmeterol/fluticasone. Although studies reporting ADRs for budesonide and beclomethasone were identified, these products were not used as intervention medication in the studies but as the comparator drug [13, 15–19].

Fig. 1 Decision tree for the review process. # Commentaries/letters to the editor (n = 6), cost-effectiveness studies (n = 2) and quality of life studies (n = 5). *A list of excluded studies is presented in Appendix 2: Meta-analyses (n = 7), efficacy studies (n = 59), non-peer reviewed articles (n = 7), studies with mixed child/adults populations (n = 16), reviews (n = 2), ADRs shown as number of children reporting an ADR (n = 43), subgroup analyses (n = 2), and an article in Chinese language (n = 1)




Table 3 Study characteristics of included studies by study population

Studies in chronological order for each ATC group	Country	Design	Dosage (µg/day)	Intervention	Comparator	Rescue medication	Observation period months (n)	Intervention patient included (n)	Intervention patients completed (n)	Comparator patients included (n)	Comparator patients completed (n)	Age (year)	% Male
<i>Beta2-agonists</i>													
Von Berg et al. [8]	Multicountry	R, DB, P	2 × 50	Salmeterol	Placebo	Yes	12	220	212	206	200	6–15	63
Von Berg et al. [9]	Multicountry	R, DB, P	2 × 4.5/9	Formoterol	Placebo	Yes	3	164	113	84	84	6–17	54
<i>Corticosteroids</i>													
Hoekx et al. [10]	Multicountry	R, DB, P	400	Fluticasone	Budesonide	Yes	2	119	100	110	91	4–13	68
<i>Leukotriene receptor antagonists</i>													
Knorr et al. [11]	CA, US	R, DB, P	5 mg	Montelukast	Placebo	Yes	2	201	189	135	125	6–14	67
Pearlman et al. [12]	Multicountry	R, DB, P	5–40 mg	Zafirlukast	Placebo	Yes	1.5	508	475	206	185	5–12	60
Storms et al. [13]	Multicountry	R, DB, P	5 mg	Montelukast	Placebo	Yes	2	201	193	135	132	6–15	67
Storms et al. [13]	Multicountry	R, O	5 mg	Montelukast	Beclomethasone	Yes	22	207	198	38	38	6–15	67
Knorr et al. [14]	Multicountry	R, DB, P	4 mg	Montelukast	Placebo	Yes	3	461	416	228	202	2–5	59
Maspero et al. [15]	Multicountry	R, O	5 mg	Montelukast	Beclomethasone	Yes	6	83	78	41	38	6–11	64
Bukstein et al. [16]	US	R, C, O	5 mg	Montelukast	Cromolyn	Yes	1	168	149	165	143	6–11	64
Garcia et al. [17]	Multicountry	R, DB, P	5 mg	Montelukast	Fluticasone	Yes	12	495	459	499	466	6–14	65
Von Adelsberg et al. [18]	Multicountry	R, DB, P	4 mg	Montelukast	Placebo	Yes	1.5	175	169	81	74	0.5–2	66
<i>Combination products</i>													
Tal et al. [19]	Multicountry	R, DB, P	160/9	Budesonide/formoterol	Budesonide	Yes	3	148	139	138	129	4–17	61
Total all studies/range							1–22	3,150	2,890	2,038	1,880	0.5–17	54–81

DB double blind, R randomized, P parallel, O open label, C cross-over, NA no information

Table 4 Reported ADRs for asthma medications leading to patient dropouts from clinical trials

Studies (chronological order for each ATC groups)	Intervention adverse drug reaction (s)	Comparator adverse drug reaction (s)
<i>Beta2-agonists</i>		
Von Berg et al. [8]	Asthma exacerbations, headache, tremor, cough	Asthma exacerbations, headache, tremor, cough
Von Berg et al. [9]	Asthma deterioration, lack of efficacy	Asthma deterioration, lack of efficacy
<i>Corticosteroids</i>		
Hoekx et al. et al. [10]	Asthma exacerbations	Asthma exacerbations, allergic skin reaction
<i>Leukotriene receptor antagonists</i>		
Knorr et al. [11]	Asthma exacerbations, pneumonia, dehydration, upper respiratory tract infection	Asthma exacerbations, urticaria
Pearlman et al. [12]	Asthma exacerbations	Asthma exacerbations
Storms et al. [13]	Yes, reactions not specified	Yes, reactions not specified
Storms et al. [13]	Yes, reactions not specified	Yes, reactions not specified
Knorr et al. [14]	Asthma exacerbations, drug overdose, rash, paraesthesia, reflux, varicella	None
Maspero et al. [15]	Abdominal pain	None
Bukstein et al. [16]	Asthma exacerbations	Asthma exacerbations
Garcia et al. [17]	Yes, reactions not specified	Yes, reactions not specified
Von Adelsberg et al. [18]	None	None
<i>Combination products</i>		
Tal et al. [19]	Asthma deterioration	Asthma deterioration

Population

A total of 3150 children were included in the studies, of which 2018 children completed the intervention treatment. The majority of completing children (78 % of total) were treated with montelukast (n = 2,326) and zafirlukast (n = 466). The other treatments were: salmeterol (n = 212); formoterol (n = 157); fluticasone (n = 100); budesonide/formoterol (n = 139). The age of the included children varied from 0.5 to 17 years. The share of male patients was higher than that of female and varied from 51 to 80 %. The reasons given for dropping out of a study were many, with the appearance of ADRs being the most frequently mentioned but generally without specification of which ADRs. Table 4 displays the information available in the articles about ADRs leading to patient dropout. Across studies asthma exacerbation was the most common cause for discontinuation [8–19].

Design

Information about ADRs was reported in clinical studies using different designs, i.e. randomized, parallel group studies (n = 10) [8–14, 17, 18], randomized open-label design (n = 2) [13, 15], and a randomized crossover study

(n = 1) [16]. The tested dosages were within the labeled dosages. Placebo was used as comparator in seven studies [8, 9, 11–14, 18] while an active comparator was administered in six studies [10, 13, 15–17, 19].

Treatment period

Treatment duration varied from 1 to 22 months across studies: between 3 and 12 months in the beta2-agonist studies [8, 9]; 2 months in the fluticasone study [10], between 1 and 22 months in leukotriene receptor antagonist studies [11–18] and 3 months in the budesonide/formoterol study [19].

ADRs by type and occurrence

Tables 5 and 6 show the ADR reporting rates (%) of paediatric patients reported in clinical trials listed in the included studies for each type of asthma medication and its comparator. Information about ADR incidence in the monitored populations was only reported if the incidence was above 2 and/or 5 %; consequently, information about rarely occurring ADRs was not reported in the articles. Overall the same categories were reported for both intervention and control groups. In the single studies no

Table 5 Reporting rates (%) of non-serious paediatric ADRs reported in published clinical trials for asthma medications by type and medication

Adverse drug reaction(s)	Intervention	Comparator
	Salmeterol	Placebo
Asthma exacerbations	47	40
Bronchitis	10	11
Cough	9	11
Fever	8	10
Headache	12	8
Sore throat	11	12
Upper respiratory tract infection	24	23
	Formoterol	Placebo
Accident/injury	4	2
Asthma exacerbations	20	17
Bronchospasm	4	7
Headache	6	8
Pharyngitis	4	5
Respiratory tract infection	28	26
Rhinitis	10	10
Viral infection	5	4
	Fluticasone	Budesonide
Allergic skin reaction	1	5
Asthma exacerbations	24	25
Cough	6	4
Ear problems	7	4
Eye disorders	13	9
Headache	3	7
Influenza	3	5
Pyrexia	4	5
Respiratory tract infection	12	15
Rhinitis	11	12
Sore throat	4	5
	Budesonide/ formoterol	Budesonide
Asthma exacerbations	5	3
Cough	5	5
Headache	6	4
Pharyngitis	8	12
Pyrexia	6	2
Respiratory tract infection	8	6
Rhinitis	7	4
Viral infection	7	3

significant differences in ADR reporting rates were detected between intervention medication and comparator treatment. The following ADRs were the most frequently reported for all tested asthma medications: asthma exacerbation, respiratory tract infection, cough, fever and

Table 6 Reporting rates (% range) of non-serious paediatric ADRs reported in published clinical trials for asthma medications by type and medication

Adverse drug reaction(s)	Intervention treatment	Comparator treatment	Placebo
<i>Montelukast</i>			
Abdominal pain	5–11	2–11	9–10
Asthma exacerbations	16–30	1–39	22–38
Bronchitis	5	NA	7
Cough	6–19	13–17	7–11
Diarrhoea	10–11	NA	8–12
Dizziness	3	11	NA
Headache	13–33	1–24	19–22
Infectious gastroenteritis	2–10	5	4
Infectious, viral	6	5	NA
Influenza	9–11	7	4
Nasal congestion	4–11	3	5
Nausea	4	NA	4
Pharyngitis	12–26	4–26	13–15
Pyrexia	8–27	5–7	4–27
Rash	11	8	NA
Respiratory tract infection	15–57	12–50	21–30
Rhinitis	12	12	NA
Rhinorrhoea	1	13	NA
Sinusitis	5–20	16	2
Tonsillitis	8	10	NA
Vomiting	1–16	3	4–20
Wheezing	7	10	NA
<i>Zafirlukast</i>			
Abdominal pain	2	NA	2
Accidental injury	2	NA	3
Asthma exacerbations	4	NA	6
Diarrhoea	2	NA	2
Flu syndrome	2	NA	3
Headache	4	NA	3
Respiratory tract infection	18	NA	28
Sinusitis	3	NA	6
Vomiting	3	NA	2

headache. In the majority of studies the study investigator collected information about ADRs. Two studies did not provide information about assessors [13, 14]. Only sparse information was provided about the scales and classification systems used to detect and assess adverse ADRs reported during the clinical trial.

ADRs by seriousness

No information about seriousness assessment was presented in the included articles. The majority of reported ADRs were classified as non-serious. Serious ADRs were reported in only few studies. Hoekx et al. [10] reported a serious allergic skin reaction from use of budesonide occurring in one person. For the treatment combination budesonide/formoterol 5 serious cases of “exacerbation of asthma” were reported [19]. In the same study two serious cases of larynx edema and pneumonia were reported [19].

Discussion

As far as we know, this is the first study to review the empirical literature on the occurrence of ADRs reported for asthma medications licensed for use in the paediatric population. Among the 162 potentially relevant studies only 12 studies (7 %) reporting information about ADRs in children were located, the majority for montelukast and zafirlukast. We found information about ADRs in large multicenter clinical studies of short duration, primarily conducted in 6- to 11-year-old boys. Leukotriene receptor antagonists were primarily studied. The most frequently reported ADRs were asthma, upper respiratory tract infection, cough, fever and headache.

Validity of reported ADRs, types and prevalence

Although the review process identified a large number of clinical trials exploring the efficacy of asthma medications in the paediatric population only a few of these reported information about ADR rates occurring in the paediatric population, therefore a large number of published clinical studies were excluded from this review. Many studies were excluded as they reported ADRs as number of children reporting the specific ADRs and not ADR rates (see appendix 2). Others were excluded because too few data about possible ADRs from use of asthma medications were reported. Due to insufficient published information, it was not possible to calculate ADR rates for many of the excluded studies. The exclusion of these studies did not result in reduced information about types of ADRs as no additional ADR categories appeared in the excluded articles. Large variations in ADR reporting rates were observed across studies and therapeutic subgroups. Similar types of ADRs were reported for the different asthma medications, such as fever, rhinitis and diarrhea, and only minor differences between ADR rates for the studied intervention and comparator were observed. These commonly reported ADRs could also be seen as normal symptoms occurring in childhood, and therefore value of

ADRs reported in the included clinical trials must be discussed further. In the studies different comparators were used, and the use of rescue medication such as short-acting beta2-agonists was also allowed in the included studies. We do not know the extent to which this practice may have affected the ADR reporting rates for intervention and comparator medication. The drugs most studied, almost 80 %, were leukotriene receptor antagonists (montelukast and zafirlukast) while in daily practice short acting beta2-agonists and ICS are recommend as first choice treatment [2]. There was preponderance in boys of the age of 6–11 years and this is in line with the predominance in asthma symptoms in younger children [20–22]. Whether the outcomes for children in these age groups apply for younger children is not clarified. There were no reports of deaths in the included studies. The SMART study found asthma-related deaths among patients >12 years treated with long acting beta 2-agonists (LABAs) and this prompted black box warnings for all LABAs in the US and restrictions in guidelines [23]. None of the ADRs commonly reported in signal detection studies such as psychiatric events and dental discoloration reported for ICS were reported in the clinical trials analyzed in the present study [6]. The reason for this discrepancy could be that the Dutch study included spontaneous ADR reports collected over a longer period of time, thus increasing the probability of detecting rarely occurring ADRs [6]. It may also be that there is no tradition for systematically observing this kind of ADRs in clinical studies of respiratory medications.

Treatment period

Although in real life children are treated for long periods of time, even years, the duration of most of the analysed studies was shorter than 6 months. This is understandable because of the high financial burden of long lasting studies. However, long-term safety is an important item for patients, parents and health care workers. As clinical trials in the paediatric population are scarce, clinicians and health authorities must rely on spontaneous reports as the main source of information about previously unknown ADRs [24]. For that aim, information from spontaneous reports to national and international databases such as the World Health Organization’ VigiBase and the European Medicines Agency EudraVigilance is essential as these databases constitute a critical source of important data, especially information about new, unlabeled, serious, and rarely occurring ADRs.

Validity of seriousness of reported ADRs

Only a small number of serious ADRs were reported. However, in several of the included studies a large number of children withdrew due to experienced ADRs and,

therefore, the actual number of serious ADRs occurring from the use of the respective asthma medications should be expected to be higher/or could be higher. Another issue is that information about definitions and scales to define and evaluate events occurring during the clinical trials was not reported in the articles and, hence, remains unknown. Low quality of reporting ADRs and lack of assessment in randomized clinical trials has been recognized before [25]. Previous studies have shown large discrepancies between the data reported in clinical trial protocols and the data published in scientific journals [25, 26]. Surveys have reported that the fears of children and parents about serious ADRs could lead to poor compliance with prophylactic treatment regimes, resulting in poor control of asthma symptoms, inappropriate use of rescue medication, increased hospitalization, and more frequent visits to general practitioners [27, 28]. This is another reason to report ADRs as accurately as possible. When performing clinical studies researchers should seek ADRs actively and they should not be dependent on spontaneous reports by parents or caregivers. As can be seen in Tables 5 and 6 not much difference between study drug and comparators were found. A statistical comparison between study drugs and comparators was, due to low number, not possible. Although it is tempting to conclude that the number of ADRs is really low, we cannot be sure that this is true, due to the abovementioned reasons.

Publication bias

Previous studies have demonstrated that not all results of clinical trial are published in the literature—especially results of clinical trials conducted in the past for older medications showing negative results with respect to efficacy and safety of the tested medications in vulnerable populations, i.e. children and elderly [28]. Due to the widespread use of beta2-agonists and corticosteroids and the small number of available studies reporting sufficient information about ADRs from use of these medications in children, the publication bias in this specific setting is probably strong, especially since all included clinical trials in the current review were funded by pharmaceutical companies.

Strengths and limitations of this review

The included clinical studies were conducted over a period of approximately 10 years in different countries and observation periods, and with a great deal of inconsistency in observation and classification of type and seriousness of reported ADRs. The variations in the observation periods could have had an impact on the number and type of reported ADRs. However, the clinical studies did not report whether ADR rates were corrected for variations in observation period. Information about the seriousness of

the reported ADRs was extracted from the included studies. As we did not have access to the original data material, it was not possible for us to evaluate these assessments, nor to estimate ADRs in terms of effect sizes. A major limitation of this study is lack of information in the clinical trials about causality assessment procedures of the reported ADRs, which has implications for the clinical interpretation of the findings. Another limitation is that we do not know whether “intention-to-treat” or “per-protocol” analysis were used in the clinical trials. Estimates of ADRs may vary substantially within the two types of analysis and may lead to important underreporting bias. The reporting system of ADRs in clinical trials does not represent the gold standard, and the clinical trials have limited duration of time in a selected population in order to collect information about ADRs. This study confirmed, that the included clinical trials did not offer information about new, unexpected, or rare occurring ADRs as expected due to the low number of included children in the trials. Therefore we suggest that further epidemiological studies in this area should be conducted.

Conclusions

Despite the large number of clinical studies on asthma medication in children, only a few studies reporting ADRs from use of asthma medications in children were identified in the literature. This study highlights some very important issues about information on ADRs of asthma medication in clinical studies. Firstly, the patients included are mostly boys in the age of 6–11 years. Information on ADRs in younger children, who are more vulnerable, is scarce. Although in practice salbutamol and ICS are used most frequently, most information on ADRs was on leukotriene receptor antagonists. Only a few serious ADRs were reported, but patients' withdrawal from clinical studies due to ADRs should be investigated more clearly. We believe that giving correct and reliable information on ADRs in asthma medication in clinical trials is a responsibility of researchers, authors, editors of journals, pharmaceutical companies, and regulatory agencies.

Acknowledgments We thank Dr. T.W. de Vries, Paediatric Department, Medisch Centrum Leeuwarden, Netherlands, for commenting on previous drafts of this manuscript. We also thank MSc (pharm) Malene Hammer Krag for assistance with quality assurance of data extractions. Furthermore we also thank the information specialists at the National Library of Denmark and Copenhagen University Library for assistance with the literature searches.

Funding No sources of funding were used to assist in the preparation of this study.

Conflicts of interest None.

References

1. Thrane N, Sørensen HT. A one-year population-based study of drug prescriptions for Danish children. *Acta Paediatr.* 1999;88:1131–6.
2. Grover C, Armour C, Asperen PP, Moles R, Saini B. Medication use in children with asthma: not a child size problem. *J Asthma.* 2011;48:1085–103.
3. Arellano FM, Arana A, Wentworth CE, Vidaurre CF, Chipps BE. Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States. *Pediatr Allergy Immunol.* 2011;22:469–76.
4. Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. *Drug Saf.* 2010;33(4):327–39.
5. Star K, Noren N, Nordin K, Edwards RI. Suspected adverse drug reactions reported for children worldwide. An explanatory study using VigiBase. *Drug Saf.* 2011;34:415–28.
6. De Vries TW, de Langen-Wouterse JJ, van Puijenbroek E, Duiverman EJ, den Berg LTW. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. *Eur J Clin Pharmacol.* 2006;62:343–6.
7. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. *PLoS Med.* 2009;6(6):e1000097. doi:10.1371/journal.pmed1000097.
8. Von Berg A, De Blic J, La Rosa M, Kaad PH, Moorat A. A comparison of regular salmeterol vs “as required” salbutamol therapy in asthmatic children. *Respir Med.* 1998;92:292–9.
9. Von Berg A, Papageorgiou F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol turbobaler in children. *Int J Clin Pract.* 2003;57:852–6.
10. Hoekx JCM, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: double-blind trial in asthmatic children using powder devices at a dosage of 400 mg/day. *Eur Respir J.* 1996;9:2263–72.
11. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6-14-year-old children. *JAMA.* 1998;279:1181–6.
12. Pearlman DS, Lampl KL, Dowling PJ, Miller CJ, Bonuccelli CM. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. *Clin Ther.* 2000;22:732–47.
13. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥ 6 years. *Clin Exp Allergy.* 2000;31:77–87.
14. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist for the treatment of persistent asthma in children aged 2 to 5 years. *Pediatr.* 2001;108:e48.
15. Maspero JF, Duenas-Meza E, Volovitz B, Daza CP, Kosa L, Vrijens F, et al. Oral montelukast versus inhaled beclomethasone in 6-11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction and adherence with therapy. *Curr Med Res Opin.* 2001;17:96–104.
16. Bukstein DA, Bratton DL, Firriolo KM, Estojak J, Bird SR, Hustad CM, et al. Evaluation of parenteral preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. *J Asthma.* 2003;40:475–85.
17. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast compared with fluticasone for control of asthma among 6-to 14-Year-old patients with mild asthma: the MOSAIC study. *Pediatr.* 2005;116:360–9.
18. Van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability and exploratory efficacy of montelukast in 6-to-24-month-old patients with asthma. *Curr Med Res Opin.* 2005;21:971–9.
19. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. *Pediatr Pulm.* 2002;34:342–50.
20. Duggan EM, Sturley J, Fitzgerald AP, Perry IJ, Hourihane JO. The 2002–2007 trends of prevalence of asthma, allergic rhinitis and eczema in Irish schoolchildren. *Pediatr Allergy Immunol.* 2012;23:464–71.
21. Beasley R, Holt S, Fabian D, Masoli M. Global burden of asthma. Global initiative for asthma (GINA). www.ginasthma.org/. Last accessed 4 July 2013.
22. National Heart Lung and Blood Institute. Guidelines for the Diagnosis and Management of Asthma (EPR-3). <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Last accessed 4 July 2013.
23. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest.* 2006;129:15–26.
24. Aagaard L, Hansen EH. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs, and NSAIDs. *BMC Clin Pharmacol.* 2009;9:4.
25. Gøtzsche P, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Constraints on publication rights in industry-initiated clinical trials. *JAMA.* 2006;295:1645–6.
26. De Vries T, Van Roon EN. Low quality of reporting adverse drug reactions in paediatric randomised controlled clinical trials. *Arch Dis Child.* 2010;95:1023–6.
27. Rogers L, Reibman J. Stepping down asthma treatment: how and when. *Curr Opin Pulm Med.* 2012;18:70–5.
28. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA.* 2004;26:2457–65.

Appendix 1: PRISMA checklist*

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	3-5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5

Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	5
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	7-8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	NA
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	5
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	5-7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8-9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	17-19
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	NA
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	NA
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	7
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	10

NA: Not relevant, * Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

Appendix 2: Excluded studies listed by reason for exclusion, alphabetically by first author

Meta-analysis

1. McMahonen AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and Risk of FDA-approved long-acting β_2 -adrenergic receptor agonists. *Pediatr* 2011;128:e1147-e1154.
2. Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. *Am J Med* 2010;123:322-28.
3. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S. Meta-analysis: Effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. *Ann Intern Med* 2008;149:33-42.
4. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. *Thorax* 2012;65:39-43.
5. Wijesinghe M, Weatherall M, Perrin K, Harwood M, Beasley R. Risk of mortality associated with formoterol: a systematic review and meta-analysis. *Eur Respir J* 2009;34:803-11.
6. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: Effect of Long-acting β -agonists on severe asthma exacerbations and asthma-related deaths. *Ann Intern Med* 2006;144:904-12.
7. Nelson H, Bonuccelli C, Radner F, Ottosson A, Carroll KJ, Andersson TLG, LaForce C. Safety of formoterol in patients with asthma: Combined analysis of data from double-blind, randomized controlled trials. *J Allergy Clin Immunol* 2010;125:390-6.

Efficacy studies without information about ADR rates

1. Estelle F, Simons R. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. *NEJM* 1997;337:1659-65.
2. Estelle F, Simons R, Soni NR, Watson WTA, Becker AB. Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma. *J Allergy Clin Immunol* 1992;90:840-46.
3. Carlsen KH, Røksund O, Osholt K, Njå F, Leergaard J, Bratten G. Overnight protection by inhaled salmeterol on exercise-induced asthma in children. *Eur Respir J* 1995;8:1852-55.
4. Fuglsang G, Vikre-Jørgensen J, Agertoft L, Pedersen S. Effect of Salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. *Pediatr Pulm* 1998;25:314-21.
5. Jarri TT, Kaila TJ, Tahvanainen KUO, Kuusela TA, Vanto TT, Välimäki AT. Altered cardiovascular autonomic regulation after salmeterol treatment in asthmatic children. *Clinical Physiology* 18;4:345-53.
6. Stelmach I, Gorski P, Jerzynska J, Stelmach W, Majak P, Kuna P. A randomized, double blind trial of the effect of treatment with formoterol on clinical and inflammatory parameters of asthma in children. *Ann Allergy Asthma Immunol* 2002;89:67-73.
7. Baki A, Karagüzel G. Short-term effects of budesonide, nedocromil sodium and salmeterol on bronchial hyperresponsiveness in childhood asthma. *Acta Paediatr Jpn* 1998;40:247-51.
8. Verini M, Verrotti A, Greco R, Chiarelli F. Comparison of the bronchodilator effect of inhaled short- and long-acting beta(2)-agonists in children with bronchial asthma: a randomized trial. *Clin Drug Invest* 1998;16:19-24.
9. Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor antagonist: double-blind comparison with salbutamol and placebo in children with asthma. *J Allergy Clin Immunol* 1989;84:891-5.
10. Fuglsang G, Agertoft L, Vikre-Jørgensen J, Pedersen S. Influence of budesonide on the response to inhaled terbutaline in children with mild asthma. *Pediatr Allergy Immunol* 1995;6:103-8.
11. Meijer GG, Postma DS; Mulder PG; van Aalders WM. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. *Am J Respir Crit Care Med* 1995;152:1887-92.

12. Kozlik-Feldmann R, von Berg A, Berdel D, Reinhardt D. Long-term effects of formoterol and salbutamol on bronchial hyperactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. *Eur J Med Res* 1996;25:465-70.
13. Verberne AA, Hop WC, Creyghton FB, van Rooij RW, van den Berg M, de Jongste JC, Kerrebijn KF. Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. *J Allergy Clin Immunol* 1996;97:938-46.
14. Zarkovic J, Gotz MH, Holgate ST, Taak NK. Effect of long-term regular salmeterol treatment in children with moderate asthma. *Clin Drug Invest* 1998;15:169-75.
15. Clark CE, Ferguson AD, Siddorn J. Respiratory arrests in young asthmatics on salmeterol. *Respir Med* 1993;87:227-8.
16. Langton Hewer S, Hobbs J, French D, Lenney W. Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma. *Respir Med* 1995;89:435-40.
17. Blake K, Pearlman DS, Scott C, Wang Y, Stahl E, Arledge T. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. *Ann Allergy Asthma Immunol* 1999;82:205-11.
18. Weinstein SF, Pearlman DS, Bronsky EA, Byrne A, Arledge T, Liddle R; Stahl E. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. *Ann Allergy, Asthma & Immunology* 1998;81:51-58.
19. SB030001. A four-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of VentolinTM HFA MDI delivered TID with facemask and valved holding chamber Aerochamber Plus in subjects birth to < 24 months in age with symptoms of bronchospasm (i.e. wheeze, cough, dyspnea or chest tightness) consistent with obstructive airway disease. 2007. Available at: www.ctr.gsk.co.uk.
20. SB030002. A randomized, double-blind, parallel-group, multi-center study of albuterol sulfate HFA inhalation aerosol delivered cumulatively with a valved holding chamber and an attached facemask in subjects between birth to 23 months of age with acute wheezing due to obstructive airway disease. 2006. Available at: www.ctr.gsk.co.uk.
21. IND/SEREACC/PMS. Post marketing surveillance (PMS) of salmeterol and fluticasone in fixed dose combination (Seretide® Accuhaler) in the treatment of bronchial asthma. 2005. Available at: www.ctr.gsk.co.uk
22. SAS107541. A long term follow up study for comparison of stepwise treatment of asthmatic children with salmeterol/fluticasone propionate combination product (SERETIDE^R) and/or fluticasone propionate (FLIXOTIDETM) based on PD₂₀ methacholine and symptoms or based on symptoms only ("Children Asthma Therapy Optimal"). 2010. Available at: www.ctr.gsk.co.uk.
23. Grønnerød TA, von Berg A, Schwabe G, Soliman S. Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. *Respir Med* 2000;94:661-67.
24. Ferguson AC, Spier S, Manjra Am Versteegh FGA, Mark S, Zhang P. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. *J Pediatr* 1999;134:422-27.
25. Agertoft L, Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. *Eur Respir J* 1997;10:1507-12.
26. Kannisto S, Voutilainen R, Remes K, Korpi M. Efficacy and safety of inhaled steroid and cromone treatment in school-age children: a randomized pragmatic pilot study. *Pediatr Allergy Immunol* 2002;13:24-30.

27. Browne GJ, Trieu L, Van Asperen P. Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department. *Crit Care Med* 2002;30:448-53.
28. Bisgaard H, Le Roux P, Bj  mer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. *Chest* 2006;130:1733-43.
29. Goggin N, Macarthur C, Parkin PC. Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. *Arch Pediatr Adolesc Med* 2001;155:1329-34.
30. Upham BD, Mollen CL, Scarfone RJ, Seiden J, Zorc JJ. Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double blind trial. *Acad Emerg Med* 2011;18:665-73.
31. Browne GJ, Penna AS, Phung X, Soo M. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. *Lancet* 1997;349:301-05.
32. Craven D, Kercksmar CM, Myers TR, O'Riordan MA, Golonka G, Moore S. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. *J Pediatr* 2001;138:51-58.
33. Schuh S, Johnson DW, Callahan S, Canny G, Levison H. Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. *J Pediatr* 1995;126:639-45.
34. Beck R, Robertson C, Galdes-Sebalde M, Levison H. Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. *J Pediatr* 1985;107:605-08.
35. Reisman J, Galdes-Sebalde M, Kazim F, Canny G, Levinson H. Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. *J Allergy Clin Immunol* 1988;81:16-20.
36. Williams J, Richards KA. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the Turbo inhaler in paediatric patients. UK study Group. *Br J Clin Pract* 1997;51:147-53.
37. Iramain R, Lopez-Herce J, Coronel J, Spitters C, Guggiari J, Bogado N. Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. *J Asthma* 2011;48:298-03.
38. Agertoft L, Pedersen S. A randomized, double blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. *J Allergy Clin Immunol* 1997;99:773-80.
39. Knorr B, Larson P, Nguyen HH, Holland S, Reiss TF, Chervinsky P, Blake K, van Nispen CH, Noonan G, Freeman A, Haesen R, Michiels N, Rogers JD, Amin RD, Zhao J, Xu X, Seidenberg BC, Gertz BJ, Spielberg S. Montelukast dose selection in 6-to14-year-olds: comparison of single-dose pharmacokinetics in children and adults. *J Clin Pharmacol* 1999;39:786-93.
40. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-14-year-old children with asthma. *J Pediatr* 1998;133:424-8.
41. Knorr B, Nguyen HH, Kearns GL, Villaran C, Boza ML, Reiss TF, Rogers JD, Zhang J, Larsen P, Spielberg S. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. *J Clin Pharmacol* 2001;41:612-19.
42. Kearns GL, Lu S, Maganti L, Li X, Migoya E, Ahmed T, Knorr B, Reiss TF. Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis. *J Clin Pharmacol* 2008;48:502-11.

43. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, Tozzi CA, Polos P. Montelukast reduces asthma exacerbations in 2-to5-year-old children with intermittent asthma. *Am J Respir Crit Care Med* 2005;171:315-22.
44. Pedersen S, Agertoft L, Williams-Herman D, Kuznetsova O, Reiss TF, Knorr B, Dass BS, Wolthers OD. Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. *Pediatr Pulmonol* 2007;42:838-43.
45. Davies GM, Dasbach EJ, Santanello NC, Knorr BA, Bratton DL. The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. *Clinical Ther* 2004;26:1895-1904.
46. Volovitz B, Tabachnik E, Nussinovitch M, Shtaf B, Blau H, Gil-Ad I, Weizmann A, Varsano I. Montelukast, a leukotriene receptor antagonist, reduced the concentration of leukotrienes in the respiratory tract of children with persistent asthma. *J Allergy Clin Immunol* 1999;104:1162-7.
47. Pohunek P, Matulka M, Rybníček O, Kopriva F, Honomichlova H, Svoboda T. Dose-related efficacy and safety of formoterol (Oxis®) Turbuhaler® compared with salmeterol Diskhaler® in children with asthma. *Pediatr Allergy Immunol* 2004;15:32-39.
48. Everden P, Campbell M, Harnden C, McGoldrick H, Bodalia H B, Manion V, Renyia S. Eformoterol Turbuhaler® compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids. *Pediatr Allergy Immunol* 2004;15:40-47.
49. Stempel DA, Riedel AA, Rosenzweig JRC. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. *Curr Med Res Opin* 2006;22:463-70.
50. Schuh S, Dick PT, Stephens S, Hartley M, Khaikin S, Rodrigues L, Coates AL. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. *Pediatr* 2006;118:644-50.
51. Aldington S, Williams M, Weatherall M, Beasley R. Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: A randomized controlled trial in childhood asthma. *Respirology* 2006;11:638-42.
52. De Blic J, Orgorodova L, Klink R, Sidorenko I, Valiulis A, Hofman J, Bennedbaek O, Anderton S, Attali V, Desfourgeres JL, Poterre M. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. *Pediatr Allergy Immunol* 2009;20:763-71.
53. Carroll WD, Jones PW, Boit P, Clayton S, Cliff I, Lenney W. Childhood evaluation of salmeterol tolerance- A double-blind randomized controlled trial. *Pediatr Allergy Immunol* 2010;336-44.
54. Vaessen-Verberne AAPH, Van den Berg NJ, van Nierop J, Brackel HJL, Gerrits GPJM, Hop WCJ, Duiverman EJ. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. *Am J Respir Crit Care Med* 2010;182:1221-27.
55. Ahlström H, Alvero J, Alvero R, Espos R, Fajutrao L, Herrera J, Kjellman B, Kubista J, Leviste C, Meyer P, Oldæus G, Siricururat A, Vichyanond P, Wettrell G, Wong E, Laxmyr L, Nyberg L, Olsson H, Weibull E, Rosenborg J. Pharmacokinetics of bambuterol during oral administration to asthmatic children. *Br J Clin Pharmacol* 1999;48:299-308.
56. Kuusela AL, Marenk M, Sandahl G, Sanderud J, Nikolajev K, Persson B, Olsson H. Comparative study using oral solutions of bambuterol once daily or terbutaline three times daily in 2-5-year-old children with asthma. *Pediatr Pulm* 2000;29:194-201.
57. Fogel RB, Rosario N, Aristizabal G, Loeys T, Noonan G, Gaile S, Smugar SS, Polos PG. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. *Ann Allergy Asthma Immunol* 2010;104:511-17.
58. Tunaoglu FS, Türktas I, Olguntürk R, Demirsoy S. Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children. *Pediatr Intern* 1999;41:28-31.

59. Croner S, Hedenskog S, Kjellman NI, Odelram H. Salbutamol by powder or spray inhalation in childhood asthma. *Allergy* 1980;35:589-92.

Non-peer reviewed articles

1. Gotz MH, Taak NK. The efficacy and safety of inhaled salmeterol (50 mcg bd) compared with salbutamol (200 mcg prn) in children with asthma. *Eur Resp J* 1995;8S:19:517s.
2. Nathan RA, Mitchell D, Condemi J, Heller A, Schoaf L, Herrle M, et al. Cardiovascular and hypothalamic-pituitary-adrenal axis safety of fluticasone propionate/salmeterol HFA MDI in adolescents and adult patients with asthma. *Am J Respir Crit Care Med* 2001;163(5):A863.
3. Pearlman DS; Bronsky E, Chervinsky P, et al. Inhaled salmeterol powder compared with placebo administered over 12 weeks to children with mild to moderate asthma. *Am J Resp Cri Care Med* 1996;153(4):A76.
4. Gotz MH, Taak NK. The efficacy and safety of inhaled salmeterol (50 mcg bd) compared with salbutamol (200 mcg prn) in children with asthma. *Eur Resp J* 1995;8S19:517s.
5. Verberne A, Lenney W, Kerribyjn K. A 3 way crossover study comparing twice daily dosing of salmeterol 25mcg and 50mcg with placebo in children with mild to moderate reversible airways disease. *Am Rev Resp Dis* 1991;143S2:20.
6. Scott C, Wu W, Ellsworth A. Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children. *Eur Respir J* 2005;26S:161.
7. Nuijsink M, Hop W, Sterk PJ, De Jongste JC, Duiverman EJ. Risk factors for moderate exacerbations in childhood asthma. *Eur Respir J* 2004;24:48S:163s.

Studies with mixtures of children and adults where children could not be identified

1. Kemp J, Wolfe J, Grady J, LaForce C, Stahl E, Arledge T, Liddle R. Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescents and adult patients. *Clin Ther* 1998;20:270-82.
2. Chervinsky P, Goldberg P, Galant S, Wang Y, Arledge T, Welch MB, Stahl E. Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial. *Chest* 1999;115:642-48.
3. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest* 2006;129:15-26.
4. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. *BMJ* 17;306:1034-37.
5. Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. *Thorax* 1991;46:105-11.
6. LaForce C, Prenner BM, Andriano K, Lavecchia C, Yegen U. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma. *J Asthma* 2005;42:101-6.
7. Agertoft L, Wolthers OD, Fuglsang G, Pedersen S. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. *Pediatr Allergy Immunol* 1993;4:152-6.
8. SFA100062. A randomized, parallel group, double-blind, comparative trial assessing lung function and other measures of asthma control in adults and adolescents, at least 12 years of age, who had either a B16-Arg/Arg, a B16-Gly/Gly or B16-Arg/Gly Genotype and are treated with fluticasone

- propionate/salmeterol DISKUS combination product 100/50 mcg or salmeterol DISKUS 50mcg BID. 2007. Available at: www.ctr.gsk.co.uk.
9. OTH112277 (AADUI). Drug use investigation for ADOAIR (fluticasone propionate/salmeterol xinafoate). Available at: www.ctr.gsk.co.uk.
 10. SAM30013. A 12-week, randomized, double-blind, parallel group study to compare the efficacy and safety of salmeterol/fluticasone propionate/GR106642X (25/50 µg x 2 inhalations) bid with fluticasone propionate (125 µg x 2 inhalations) bid in adolescents and adult patients with mild to moderate asthma. 2005. Available at: www.ctr.gsk.co.uk.
 11. Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. *Clin Ther* 2007;29:1390-402.
 12. Williams B, Noonan G, Reiss TF, Knorr B, Guerra J, White B, Matz J. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. *Clin Exp Allerg* 2000;31:845-54.
 13. Zeiger RS, Bird SR, Kaplan MS, Schatz M, Pearlman DS, Orav EJ, Hustad CM, Edelman JM. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. *Am J Med* 2005;118:649-57.
 14. Lu S, Liu N, Dass SB, Reiss TF. A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. *J Asthma* 2009;46:465-9.
 15. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-Week Multicenter Study. *Clinical Ther* 1997;19:675-90.
 16. Bailey W, Castro M, Matz J, White M, Dransfield M, Yancey S, Ortega H. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. *Curr Med Res Opin* 2008;24:1669-82.

Reviews

1. Adkins JC, McTavish D. Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma. *Drugs* 1997;54:331-54.
2. Boner A. Salmeterol: long term studies in children. *Eur Resp J* 1992;5:318s.

ADRs shown as number of children reporting ADRs

1. Pohunek P, Kuna P, Jorup C, Boeck KD. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. *Pediatr Allergy Immunol* 2006;17:458-65.
2. Lenney W, Pedersen SP, Boner AL, Jenkins MM. Efficacy and safety of salmeterol in childhood asthma. *Eur J Pediatr* 1995;154:983-90.
3. Verberne AAPH, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One-year treatment with salmeterol compared with beclomethasone in children with asthma. *Am J Respir Crit Care Med* 1997;156:688-95.
4. Verberne AAPH, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. *Am J Respir Crit Care Med* 1998;158:213-19.
5. Weinstein S, Chervinsky P, Pollard SJ, Bronsky EA, Nathan RA, Prenner B, Howland WC, Stahl E, Liddle R. A one-week dose-ranging study of inhaled salmeterol in children with asthma. *J Asthma* 1997;34:43-52.

6. Russell G, Williams DAJ, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. *Ann Allergy Asthma* 1995;75:423-28.
7. SB030003. An Open-Label, Multi-Center study to evaluate the performance and patient satisfaction of albuterol HFA with counter in asthma or COPD subjects at least 4 years of age. 2005. Available at: www.ctr.gsk.co.uk.
8. SB020001. A four-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of VentolinTM (albuterol) HFA MDI delivered with facemask and two different holding chambers in subjects aged 24 to < 48 months with asthma symptoms (i.e. wheeze, cough, dyspnea or chest tightness) or consistent with asthma or obstructive airway disease or bronchospasm. 2005. Available at: www.ctr.gsk.co.uk.
9. VIAPEAD 102318. Steroid-sparing with the salmeterol/fluticasone propionate 50/100 µg bid combination compared to fluticasone propionate 200 µg bid alone in the management of children and adolescents with moderate persistent asthma. 2008. Available at: www.ctr.gsk.co.uk.
10. SAS110099. Clinical assessment of GW815SF (SLM/FP) HFA MDI in pediatric patients with bronchial asthma – a study to compare GW815SF HFA MDI with concomitant treatment with salmeterol xinafoate dry powder inhaler (DPI) plus fluticasone propionate DPI to assess long-term safety of GW815SF HFA MDI. 2008. Available at: www.ctr.gsk.co.uk.
11. SAS110101. Clinical assessment of GW815SF HFA MDI in paediatric patients with bronchial asthma – a long term (24-week) study. 2008. Available at: www.ctr.gsk.co.uk.
12. ADA113872. A randomized, double blind, parallel group study if FSC 100/50 and FP100, both twice daily, in a pediatric population during the fall viral season. Available at: www.ctr.gsk.co.uk.
13. ADERE PEDIATRIC 1. Prospective, parallel-group, randomized, open label study to evaluate the impact of additional guidance from the health professionals team on treatment compliance of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the combination salmeterol/fluticasone propionate 50/250mcg (Seretide) twice a day. ADERE PROJECT (Pediatric). 2005. Available at: www.ctr.gsk.co.uk.
14. FAS4008 double blind period (1 year). An interventional three year study for asthma control – in what way and in what kind of population is it possible to get asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalize quality of life? 2007. Available at: www.ctr.gsk.co.uk.
15. RPS30001/SFCF3002. A multicenter, randomized, double-blind, double-dummy, parallel-group study to establish equivalence of the fluticasone propionate/salmeterol combination product (FSC) product (100/50µg) via either the reservoir powder inhalation device (RPID) or via the Diskus inhaler over 12 weeks in children with asthma. 2004. Available at: www.ctr.gsk.co.uk.
16. SAM101667. A multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of salmeterol/fluticasone propionate combination product (Seretide®) 50/100 mcg with fluticasone propionate (Flixotide®) 200 mcg, both delivered twice daily via the DISKUS inhaler, in the treatment of children aged 6-16 years with symptomatic asthma. Available at: www.ctr.gsk.co.uk.
17. SAM 103848. Pediatric asthma clinical effectiveness study (PEACE). A randomized, double-blind, double dummy, parallel group comparative clinical study of salmeterol/fluticasone (SFC) propionate inhalation powder (50/100 mcg BID) via DISKUS with oral montelukast (5 mg QID) chewable tablets in children 6-14 years of age with persistent asthma. 2008. Available at: www.ctr.gsk.co.uk.
18. SAM104926. A multicenter, randomized, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SERETIDETM) at a dose of 50/100 µg twice daily and fluticasone propionate (FLIXOTIDETM) at a dose of 200 µg twice daily, both delivered via a dry powder inhaler (DISKUSTM) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose. 2007. Available at: www.ctr.gsk.co.uk.

19. Van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL, Davies PI. Salmeterol/fluticasone propionate (50/100 µg) in Combination in a DiskusTM Inhaler (SeretideTM) is effective and safe in children with asthma. *Pediatr Pulm* 2000;30:97-105.
20. Bracamonte T, Schauer U, Emeryk A, Godwood A, Balsara S. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the DiskusTM or pressurized metered-dose inhaler in children with asthma. *Clin Drug Invest* 2005;25:1-11.
21. SFA100316. A stratified, multicenter, randomized, double-blind, parallel group, 4-week comparison of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID versus fluticasone propionate DISKUS 100mcg BID in the pediatric and in adolescent subjects with activity-induced bronchospasm. 2006. Available at: www.ctr.gsk.co.uk.
22. SFA106484. A randomized, double-blind, double-dummy, parallel-group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 inhalations of 50mmcg) twice daily in subjects 4-11 years of age with persistent asthma. 2008. Available at: www.ctr.gsk.co.uk.
23. SFA100314. A stratified, multicenter, randomized, double-blind, parallel group, 4-week comparison of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID versus fluticasone propionate DISKUS 100mcg BID in the pediatric and in adolescent subjects with activity-induced bronchospasm. 2006. Available at: www.ctr.gsk.co.uk.
24. SAS30021. A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma. 2004. Available at: www.ctr.gsk.co.uk.
25. SAS10016. A 2-week, randomized, double-blind, parallel-group study in pediatric subjects with asthma aged 4 to 11 years to examine the pharmacokinetics (PK) of fluticasone propionate (FP) and salmeterol (SALM) from the FP/SALM combination product administered twice daily via the DISKUS (FP 100mcg/SALM 50 mcg) and the FP DISKUS (FP 100 mcg) – Incorporating a population pharmacokinetic analysis with additional data provided from study SAS30031. 2005. Available at: www.ctr.gsk.co.uk.
26. SAS105519. A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4-11 years, to compare systematic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair® HFA 45/21 mcg (2 inhalations), Advair HFA 45/21 mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily. 2007. Available at: www.ctr.gsk.co.uk.
27. SAM40121. Summary of the efficacy and safety of salmeterol 50mcg and fluticasone propionate 100mcg administered in Diskus Dry Powder Inhaler twice daily in steroid experienced children with reversible airways obstruction. 2005. Available at: www.ctr.gsk.co.uk.
28. SAM40101. A pilot single centre randomized, double blind, crossover study to demonstrate the superiority of salmeterol/fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years. 2006. Available at: www.ctr.gsk.co.uk.
29. SAM40100. Randomized, double blind, comparator study to demonstrate the superiority of salmeterol/fluticasone propionate combination DISKUSTM 50/100mcg bd over fluticasone propionate DISKUSTM/AccuhalerTM 200mcg bd with respect to airway physiology in asthmatic children treated for 6 weeks. 2006. Available at: www.ctr.gsk.co.uk.
30. SAM40032. A multi-centre, open label study to demonstrate the efficacy and tolerability of Seretide Accuhaler 50/100, 50/250 or 50/500µg twice daily after substituting for budesonide or beclomethasone

- dipropionate in doses of 500µg up to 2000µg daily in subjects with reversible airways obstruction. 2005. Available at: www.ctr.gsk.co.uk.
31. SAM40012. A multicenter, randomized, double-blind, double-dummy, parallel-group comparison of three treatments: 1)salmeterol/fluticasone propionate (SFC) (50/100mcg strength) bd via DISKUS/ACCUHALER inhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4-11 years with asthma. 2004. Available at: www.ctr.gsk.co.uk.
 32. SAM3802. An observational study to assess the health related quality of life impact of treating poorly controlled asthmatic children with Seretide™ 50/100mcg. Available at: www.ctr.gsk.co.uk.
 33. Bensch G, Berger WE, Blokhin BM, Socolovsky AL, Thomson MH, Till MD, Castells J, Cioppa GD. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. *Ann Allergy Asthma* 2002;89:180-90.
 34. Morice AH, Peterson S, Beckman O, Kukova Z. *Pulm Pharm Ther* 2008;21:152-59.
 35. Migoya E, Kearns GL, Hartford A, Zhao J, van Adelsberg J, Tozzi CA, Knorr B, Deutsch P. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. *J Clin Pharm* 2004;44:487-94.
 36. Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal JL, Dass SB, Reiss TF, Knorr BA. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. *Am J Respir Crit Care Med* 2008;178:854-60.
 37. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6-to 14-year-old patients with mild asthma: The MOSAIC study. *Pediatr* 2005;116:360-69.
 38. Bracamonte T, Schauer U, Emeryk A, Godwood A, Balsara S. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the Diskus™ or pressurized metered-dose inhaler in children with asthma. *Clin Drug Invest* 2005;25:1-11.
 39. Zarkovic J, Marenk M, Valovirta E, Kuusela AL, Sandahl G, Persson B, Olsson H. One-year safety study with bambuterol once daily and terbutaline three times daily in 2-12-year-old children with asthma. *Pediatr Pulm* 2000;29:424-29.
 40. Sekhsaria S, Alam M, Sait T, Starr B, Parekh M. Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta₂-agonist in asthmatic children under age 5. *J Asthma* 2004;41:575-82.
 41. Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, Dorinsky P. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. *Ann Allergy Asthma* 2005;95:66-71.
 42. Dubus JC, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, Huiart L. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age and device. *Allergy* 2001;56:944-48.
 43. Simons FER, Villa JR, Lee BW, Teper AM, Lyttle B, Ariztizabal G, Laessig W, Schuster A, Perez-Frias J, Sekerel BE, Menten J, Leff JA. Montelukast added to budesonide in children with persistent asthma: a randomized, double blind, crossover study. *J Pediatr* 2001;138:694-8.

Subgroup analysis

1. Pohunek P, Tal A. Budesonide and formoterol in a single inhaler controls asthma in adolescents. *Int J Adolesc Med Health* 2004;16:91-105.
2. Bousquet J, Gaugris S, Kocavar VS, Zhang Q, Yin DD, Polos PG, Bjerrmer L. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. *Clin Exp Allergy* 2005;35:723-27.

Article in Chinese

1. Yang ZN, Wu Y, Pu HP. Comparative study on the clinical efficacy and safety of inhaled corticosteroid combined with slow-release theophylline compared to Seretide in the control of asthma in children [article in Chinese]. *Zhonghua Er Ke Za Zhi*. 2007; 45:784-5.